1?,25-dihydroxyvitamin D3 induced growth inhibition of PC-3 prostate cancer cells requires an active transforming growth factor beta signaling pathway

This publication has 38 references indexed in Scilit:

• p53 Is Required for 1,25-Dihydroxyvitamin D3-Induced G0 Arrest But Is Not Required for G1 Accumulation or Apoptosis of LNCaP Prostate Cancer Cells
  Endocrinology, 2003
• Anti-Tumor Effects of 1,25-Dihydroxyvitamin D3 and Vitamin D Analogs
  Current Pharmaceutical Design, 2000
• Calcitriol-Induced Apoptosis in LNCaP Cells Is Blocked By Overexpression of Bcl-21
  Endocrinology, 2000
• Antiproliferative Effect of 1α,25-Dihydroxyvitamin D3 in Human Prostate Cancer Cell Line LNCaP Involves Reduction of Cyclin-Dependent Kinase 2 Activity and Persistent G1 Accumulation
  Endocrinology, 1998
• Effects of vitamin D3 on proliferation of cancer cells in vitro
  Cancer Letters, 1997
• 1,25-Dihydroxyvitamin D3 and 9-cis-Retinoic Acid Act Synergistically to Inhibit the Growth of LNCaP Prostate Cells and Cause Accumulation of Cells in G1*
  Endocrinology, 1997
• Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines
  Molecular and Cellular Endocrinology, 1997
• Vitamin D and Prostate Cancer
  Published by Springer Nature ,1995
• Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines.
  Endocrinology, 1993
• Cyclic AMP induces transforming growth factor beta 2 gene expression and growth arrest in the human androgen-independent prostate carcinoma cell line PC-3.
  Proceedings of the National Academy of Sciences, 1992